Novaferon

Summary

Novaferon is a computationally optimized recombinant interferon-alpha variant developed in China. It has been approved in China for treatment of chronic hepatitis B and C and has been investigated for antiviral and antitumor applications. During the COVID-19 pandemic, it was also studied as a potential antiviral agent. It demonstrates potent antiviral activity with a potentially improved tolerability profile relative to conventional interferon-alpha.

Mechanism of Action

Novaferon is a computationally designed recombinant protein derived from interferon-alpha. It binds to type I interferon receptors (IFNAR1/IFNAR2), activating the JAK-STAT signaling pathway (JAK1/TYK2), leading to antiviral, antiproliferative, and immunomodulatory effects. Its engineered sequence aims to enhance antiviral potency and reduce side effects compared to natural interferon-alpha.

Routes of Administration

Goals & Uses

• Chronic Hepatitis C treatmentAntiviralModerate
• Antitumor activityOncologyLow
• Chronic Hepatitis B treatmentAntiviralModerate
• ImmunomodulationImmunologyLow
• COVID-19 antiviral therapyAntiviralLow

Contraindications

• Severe psychiatric disordersPsychiatricHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Severe cytopeniasHematologicModerate
• Severe hepatic decompensationHepatic ImpairmentHigh
• Autoimmune hepatitisHepatic / AutoimmuneHigh
• Hypersensitivity to interferonsAllergyHigh

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalCommon
• Injection site reactionsLocalCommon
• Neuropsychiatric effectsNeurological / PsychiatricUncommon
• Thyroid dysfunctionEndocrineUncommon
• MyelosuppressionHematologicCommon
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers

Drug Interactions

• Zidovudine (AZT)Moderate
• RibavirinLow
• TheophyllineModerate
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• Renal impairmentOrgan ImpairmentRelative
• Patients with autoimmune conditionsImmunologicRelative
• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveAbsolute
• Elderly patientsAgeRelative

Regulatory Status

• European UnionUnapprovedNot approved by the EMA.
• United StatesUnapprovedNot approved by the FDA; not part of any NDA or BLA as of available data.
• United KingdomUnapprovedNot approved by the MHRA.

Approved by the National Medical Products Administration (NMPA) of China for chronic viral hepatitis indications. Not approved by FDA or EMA. Investigated under clinical trials in China for multiple viral infections including COVID-19.

Evidence & Sources

No sources recorded yet.